• Through three acquisitions, EverGen Infrastructure Corp. has rapidly emerged as a leading player in the RNG market with its specialization in waste-to-energy
• EverGen owns the first producing RNG facility in Western Canada and calls municipalities and FortisBC as customers
• EverGen recently signed an LOI to expand into Alberta through the acquisition of 67% of a RNG project that has already been contracted to supply RNG to FortisBC

To many, a waist-deep heap of rotting food and agricultural waste is just garbage, but to Chase Edgelow, Chief Executive Officer of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), it is a valuable resource and opportunity to generate profits while doing something good for the planet. Less than two years from inception, EverGen, which brands itself as Canada’s Renewable Natural Gas (“RNG”) Infrastructure Platform, has established itself as a pioneer in the RNG market, snapping up several facilities in the process, including penning an LOI for a controlling stake in in a biogas facility in Alberta in March. RNG, a term used to describe biogas upgraded as a substitute for fossil natural gas, is critical to a clean energy future. Produced from any number of feedstocks, including municipal solid waste, livestock, food, and material from digesters at wastewater treatment plants, RNG can be used in many applications, including heating and cooling, electricity generation, and fuel for many different types of vehicles, amongst other things. This, in turn, saves not only on natural resources, but eliminates all the pollution from the extraction and downstream processes. Moreover, using the organic waste as feedstock can have a meaningful impact on the reduction of ozone-damaging methane emissions created through other disposal methods. Infinity Business Insights sees a thriving global RNG market undergoing 42.1% compound annual growth that will take it from $5.3 billion in 2021 to $62.1 billion by 2028. It is with good reason that Canadian companies including Enbridge Inc., ATCO Energy Solutions, and FortisBC have initiatives ongoing in the space. FortisBC’s has a stated target to have at least 15% of its gas supply carbon neutral by 2030. Headquartered in Vancouver, British Columbia and incorporated in May 2020, EverGen has quickly made a name for itself in its mission to own and operate a portfolio of RNG, waste-to-energy, and related infrastructure projects throughout North America.  With an initial focus in Western Canada, the company operates three facilities through its wholly owned B.C.-based subsidiaries: Net Zero Waste Abbotsford Inc. (“NZWA”), Sea to Sky Soils and Composting Inc. (“SSS”) and Fraser Valley Biogas Ltd. (“FVB”). All three companies were acquired by EverGen in a four-month span from December 2020 to April 2021. FVB has the distinction of being the first producing RNG project in Western Canada from its facility in Abbotsford. It also was the first project to produce RNG into FortisBC’s network. The facility combines anaerobic digestion and biogas upgrading to produce RNG, primarily by converting agricultural waste from local dairy farms. EverGen also generates revenue (in fact, historically most of its revenue) through processing inbound organics, yard waste and biosolids into high-quality organic compost under long-term contracts with municipalities. However, the trend towards RNG is accelerating as the push for a circular energy economy gains momentum. In its favor, EverGen has some powerful relationships and customers in municipalities and FortisBC, an electricity and natural gas distribution utility serving approximately 1.2 million British Columbians. In addition to the FVB/FortisBC agreement, the relationship was deepened last April when FortisBC and NZWA agreed to a 20-year offtake agreement. Per the agreement, which was approved by the British Columbia Utilities Commission in October, FortisBC will purchase up to 173,000 gigajoules of RNG annually from NZWA for injection into its natural gas system. The project is expected to convert municipal and commercial organic waste into enough energy to meet the needs of approximately 1,900 residential homes. From this existing platform, EverGen plans to further develop RNG facilities to provide offtake to FortisBC and other creditworthy buyers under long term contracts. With the regulatory path now clear and development and construction ongoing, NZWA expects to be supplying FortisBC with its RNG by early 2023. EverGen, which completed its initial public offering that raised CDN$20.0 million in August, generated CDN$1.94 million in revenue during the third quarter, bringing the total for the first nine months of 2021 to CDN$6.87 million. In March, EverGen took its first step to expand the next province over, executing a letter of intent with Grow the Energy Circle Ltd (“GrowTEC,” the general partner of CKPPQ Farms LP), to acquire a 67% interest in a biogas facility in Alberta. The LOI also stipulates that the two companies will collaborate on developing and expanding the renewable gas output at such facility, a “cornerstone” project allowing EverGen to continue participating in the consolidation and growth of the RNG industry. EverGen has agreed to pay CDN$6.6 million for the controlling interest though CDN$3.3 million in cash and the balance through issuance of 600,000 shares of common stock at a deemed value of CDN$5.50 per share, a 19.8% premium to the price of the stock the day before the LOI was executed. GrowTEC, located on the Perry Family farm near Lethbridge, Alberta, is a multi- faceted bioenergy venture of sustainable agriculture, integrating responsible best practices and renewable energy. The acquisition dovetails perfectly with EverGen’s growth agenda, as GrowTEC is developing a project that include a farm-scale anaerobic digester that converts biodegradable waste into biogas, subsequently upgrading it to RNG. FortisBC is again in the mix, with the utility committed to buying RNG produced at the farm under an offtake agreement. The project is currently in Phase 1, which is expected to be producing 80,000 gigajoules of RNG per annum starting in Q3 2022. Upon the EverGen investment, the two parties will work to increase production to 140,000 gigajoules of RNG annually. “We are thrilled to be partnering with GrowTEC and working with the Perry Family Farm on EverGen’s first project in the Alberta market,” said Edgelow in a press release on the LOI. “As we expand our RNG infrastructure platform, we are focused on investing in truly sustainable operations that contribute to carbon-negative energy production and positively impact climate change initiatives,” he added. EverGen shareholders will be on the lookout for the completion of the transaction, which is expected to happen before summer arrives. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Agriculture generates approximately 19-29% of total global greenhouse gas emissions and also has the highest demand for ammonia, at 80% globally
• This demand for ammonia is contributing to an increase in greenhouse gas emissions, through its production and additional processes
• FuelPositive seeks to remedy this situation with its on-site green ammonia production technology
• Through its decentralized agricultural positioning model, the company aims to reduce ammonia’s overall carbon footprint while also empowering farmers by giving them fertilizer and energy independence and control over supply and costs

Experts have noted, with great concern, that the current food production and distribution systems are already at a breaking point. They have cited the need to feed a growing global population as one of the key factors creating tremendous pressure on a structure that, they note, has been pushed to its environmental limits (https://ibn.fm/H3EIb). FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) recognizes this issue and, through its green ammonia technology, the company is trying to remedy the situation and offer solutions that are not only sustainable but also accessible, even to the ordinary farmer. Over the years, the agricultural sector has dealt with various challenges, from an aging and shrinking workforce to a significant loss of arable land and, more importantly, the potentially disastrous effects of climate change. According to a report from The World Bank, agriculture remains a significant part of the climate problem, generating approximately 19-29% of total global greenhouse gas (“GHS”) emissions (https://ibn.fm/ypSHv). In addition, agriculture is the sector with the highest demand for ammonia, accounting for over 80% globally. Ammonia is integral for adding nitrogen into the soil, an element that is essential for plant growth and plant health. Usually, the nitrogen is depleted by growing crops, prompting farmers to replenish it using ammonia. The issue, however, arises from ammonia production. Typical manufacturing of this product is energy-intensive and centralized, resulting in some of the world’s most concentrated greenhouse gas emissions. Additionally, there is an issue with supply chain interruptions and wild price fluctuations that affects farmers and adds to other processes that only increase the carbon footprint. FuelPositive seeks to remedy the situation with its decentralized agriculture positioning for its green ammonia. For starters, the company’s product aims to give farmers fertilizer and energy independence. With every farm housing a FuelPositive production unit scaled up or down based on its needs, the farmers will produce sufficient ammonia to fertilize their crops and even power their internal combustion engines in their farm equipment, and generators on the farm (https://ibn.fm/qntgM). This opens even more opportunities for farmers, including converting propane and natural gas crop-drying systems to burn green ammonia as a way to realize an exceptional environmental benefit. This decentralized approach eliminates the traditional supply chain, which is wildly unpredictable, both in supply and cost. Farmers will have control over the amount of ammonia and fuel they produce and when it will be available to them. They will be able to plan on a steady price, giving them a chance to increase their margins and improve their livelihoods from their farming activities. In addition, from an environmental standpoint, the unique ammonia production process eliminates reliance on fossil fuels, and the decentralization of the production facilities negates ammonia’s overall carbon footprint, allowing for a healthier planet. FuelPositive is able to help the agricultural sector reduce its overall greenhouse gas emissions while providing more opportunities for farmers to make a decent living from their operations. In addition, through its push for green ammonia and its push for more farmers to access it, the company is creating even more value for its shareholders. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”
• Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically
• SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications

“The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo has long been familiar with the potential of psychedelics. “It’s been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds,” reported the Times, noting that psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. “Even as antidrug campaigns led to the criminalization of Ecstasy, LSD and magic mushrooms, and drove most researchers from the field, Dr. Doblin continued his quixotic crusade with financial help from his parents. “Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward on Monday when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as Ecstasy and Molly,” the article continued. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder.” The article observed that only a few weeks ago, the “New England Journal of Medicine” also published a study highlighting the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms. These studies “have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later. After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction. The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.” This urgency aligns with Silo Pharma’s mission identifying assets to license while funding transformative research for the well-being of patients and the healthcare industry. The company focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications. Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• TravelAdvisor survey shows demand for travel remains high with majority of respondents likely to travel this year
• Survey also reports that the average spend per trip for 2022 is estimated to be beyond that of 2019
• SHRG’s new company will offer tremendous savings, exclusive benefits to its members

Calling 2022 “the year of the travel rebound,” TripAdvisor announced results of a recent survey indicating that traveler intent for this year demonstrates high demand for booking experiences and a willingness to spend more on travel (https://ibn.fm/YL42V). This is great news for Sharing Services Global (OTCQB: SHRG), which last year launched a new travel company, a direct-selling division focused on providing exclusive benefits and first-class discount travel opportunities (https://ibn.fm/Rh3O9). The TripAdvisor report, which was conducted in partnership with Ipsos MORI, indicates how consumers are planning to travel in 2022 and beyond, and how their attitudes toward and plans for travel have changed compared to prepandemic. “While outside factors like COVID-19 variants, international travel rules and staffing shortages still can represent existential threats to traveler behaviors, year-end sentiment and search data show ongoing demand for travel remains high,” a summary of the report stated. “Who benefits from the tourism demand? As travelers spend more, cultural experience providers (tours and attractions), tourism businesses catering to domestic audiences and companies adhering to safety standards will win the hearts and minds of travelers.” The survey, which was conducted in November 2021, included more than 10,000 participants aged 18 to 75 in the United States, United Kingdom, Australia, Singapore and Japan. Respondents were asked about their sentiments regarding their future travel inclinations, when they plan to travel, and what they’re looking for in a trip when they do. Across the five markets, the majority of respondents indicated that they were either very likely or fairly likely to travel for leisure, to travel to visit friends or family, or to travel for business purposes this year. Specifically, the report noted that “respondents in Singapore were the most likely to say they will travel in 2022 at 89%, followed by respondents in the UK at 85%. Australia and the United States fell in the middle of the five markets surveyed, with 79% and 78%, respectively, saying that they are likely to travel for those reasons in 2022. Japanese respondents were the least likely to say they will travel in 2022, with 58% saying that they are likely to do so — still a healthy proportion of people despite being the lowest of the five markets surveyed.” In addition, TripAdvisor reported that the average amount spent per trip for 2022 is estimated to be beyond that of 2019, as travelers look to level up their travel experience. According to Tripadvisor, American travelers are expected to spend 29% more on their average trip in 2022 than they did in 2019, while in Australia, average booking rates are expected to be up by 16% in 2022 against 2019. Singaporean travelers’ booking values are also expected to increase this year. SHRG’s news of its travel company, one of its Hapi Brands subsidiaries, will be ideally positioned to benefit from these upward trends. According to Sharing Services, to differentiate itself from its competitors, the new company will offer its members unfettered access to tremendous savings and exclusive benefits on a level not seen in the industry before. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com, www.TheHappyCo.com, and www.HapiTravel.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors
• The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier
• The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors
• By crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central nervous system cancers annually

This year, about 25,050 adults (14,170 men and 10,880 women) will be diagnosed with malignant central nervous system (“CNS”) tumors – cancerous tumors that start in the spinal cord or brain. The figure represents an increase from an estimated 24,530 cases documented last year. Of these statistics, the American Society of Clinical Oncology (“ASCO”) notes that brain tumors account for 85-90% of all primary CNS tumors (https://ibn.fm/c9ThB). But despite this prevalence, the treatment of brain tumors has long been complicated by the brain’s internal workings. A healthy human brain has a mechanism known as the blood-brain barrier that protects the active functions of the CNS and blocks toxins and microorganisms from passing through the highly picky semipermeable border. While this barrier promotes stability of the sensitive internal environment of the brain, it complicates the treatment of brain tumors. Most notably, it hinders the vascular delivery of various therapeutic substances, including anthracyclines, to the cancerous growths within the brain’s internal environment (https://ibn.fm/YZGPK). “[Anthracycline] is a classic drug that’s been around for 60 years. It’s the first line therapeutic for all sorts of difficult-to-treat cancers. But no one has been able to get a drug like this across the blood-brain barrier until our Founder modified the classic anthracycline molecule to be more effective in crossing the blood-brain barrier,” CNS Pharmaceuticals (NASDAQ: CNSP) President & CEO John Climaco told Proactive last fall (https://ibn.fm/em55b). Following the modifications, now woven into the company’s lead product candidate, Berubicin – a novel anthracycline designed to concentrate in tumor tissue within the brain – CNS Pharmaceuticals is targeting the treatment of glioblastoma multiforme (“GBM”). GBM, also known as a grade IV astrocytoma, is the most malignant, aggressive, and common form of astrocytoma – a type of brain cancer – and is one of the most treatment-resistant cancers that form in the brain (https://ibn.fm/fed4R). Historically, a GBM diagnosis often led to a prognosis of months or less to live. But this narrative is changing, with research and clinicians’ work helping prolong patients’ lives. Founded in 2017, CNS Pharmaceuticals is leading the charge toward advancing research on the treatment for GBM as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of Berubicin for the treatment of GBM, dosing its first patients in September (https://ibn.fm/cE5xu). The company expects to report an interim analysis of the trial when 30-50% of the planned subjects reach six months in-study, potentially in the first half of 2023. The adaptive, multicenter, open-label, randomized, and controlled study will involve about 243 adult patients with recurrent GBM after failure of standard first-line therapy. The subjects will be randomized in a 2:1 ratio to receive Berubicin or lomustine, a compound used in chemotherapy, to evaluate Overall Survival, the study’s primary endpoint. The study is expected to potentially build on the Phase 1 trial and pharmacokinetic study of Berubicin, whose results revealed that 44% of the patients showed clinical response of stable disease or better, with one patient demonstrating a lack of detectable cancer cells and two patients with partial tumor reduction of up to 80%. In a recent update, CNS Pharmaceuticals also celebrated the production of a new mesylate salt of its WP1244 drug technology, now known as WP1874, whose improved solubility may enhance its ability to be formulated for use in an IV infusion. WP1874 is believed to retain the potency and toxicity attributes of WP1244, which, in turn, was shown to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Moving forward, CNS Pharmaceuticals expects to primarily focus its development efforts of the WP1244 portfolio on the newly minted WP1874. The company is also investigating the use of WP1244/WP1874 in treating other primary CNS cancers as well as brain metastases such as pancreatic, ovarian, and lymphoma (https://ibn.fm/CLVDb). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Recent study forecasts global mental health market to reach almost $538B by 2030
• One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more
• Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders

A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN) is establishing itself as a leader in revolutionizing mental health treatments. “Mental health problems are characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms,” the recent Allied Market Research report states. “Increase in prevalence of mental disorders, rise in geriatric population, and growth in awareness programs regarding mental health drive the market growth. Moreover, growing awareness about mental disorders through education and advocacy for more respect of human rights and less stigma drive the growth of the global mental health market.” Noting that one in five people in the United States suffers from mental illness, the report cites alcohol use disorders, bipolar disorder, depression, anxiety, post-traumatic stress disorder, substance abuse disorders, and eating disorders as some of the major categories in the mental-health space. The study reported that the depression segment dominates the market and is expected to continue this trend throughout the forecast period. “Factors such as genes as well as stress and brain chemistry lead to depression,” the report states. “According to the WHO, more than 264 million people of all ages suffered from depression in 2020. Depression is a leading cause of disability worldwide, and is a major contributor to the overall global burden of disease.” In its commitment to transform the mental health treatment landscape, Cybin is combining novel psychedelic molecules with controllable drug-delivery systems through its proprietary deuterated process, thus creating patent-protected, commercially scalable drug candidates. The company currently is moving three of these drug candidates forward: CYB003, CYB004 and CYB005 (https://ibn.fm/bqIt6). Cybin’s active drug programs target major depressive disorder (CYB003), alcohol use disorder (CYB003), anxiety disorders (CYB004) and neuroinflammation (CYB005).  The company recently announced that it commenced a company-sponsored feasibility study with its partner Kernel to evaluate Kernel’s quantitative neuroimaging technology, Kernel Flow(R). The Flow headset, which is equipped with hi-tech sensors, will be used to collect and quantify longitudinal brain activity before, during and after a psychedelic experience. Cybin also has 50 novel compounds developed with multiple patent filings across three patent families. In terms of investor interest, Cybin has raised $120 million to date to support its clinical trials and M&A strategy. In addition, the company is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Friendable has seen a positive month over month growth trend across Facebook, Instagram and Twitter (3.8%) that is almost four times the industry average
• The current metrics, as described by CEO Robert A. Rositano, Jr. are key indicators of the company’s market penetration and next stages of growth
• The Fan Pass Live April contest will give the top five ticket selling artists the opportunity to win free music distribution for an entire year

Friendable (OTC: FDBL), a mobile technology and marketing company, has announced the addition of social media platform TikTok to its social media engagement and marketing efforts. The decision comes as the company continues to see a positive month-over-month trend across other platforms – with an overall positive engagement rate of 3.8% on Facebook, Twitter, and Instagram (https://ibn.fm/Rq03E). The industry average for social engagement rate for media is only 1%. Friendable also reported an overall increase of 5.4% for March 2022 across the three platforms (before commencing TikTok campaigns). Robert A. Rositano, Jr., CEO of Friendable, explained that, as the company’s artist platform, business model and full 360 suite of services have become available, the team has been focusing its attention on extending reach, brand awareness, and partnerships, that provide more exposure to the company’s offerings. “In addition to being excited about the launch of TikTok to our digital campaigns, we have also achieved a 60.4% increase on Facebook page likes and increased our engagement rate by 7%, with the impression rate increasing by another 1.4%,” Rositano Jr. added. “Thank you to our team, our partners, and our shareholders, please stay tuned as we continue trending upward in what we believe are key indicators of our market penetration and preparation for next stages of growth.” Key Insights – March 2022 – Facebook, Instagram, and Twitter Total audience growth for the three platforms during March was up 6.1%, with the overall engagement rate increasing to 6.3%. Both Artist Republik and Fan Pass Live saw increases across social platforms: Artist Republik Facebook:

• Page Reach up 26%
• Post Engagement up 257%
• Page Likes up 70%

Instagram:

• Account Reach up 71.2%
• Account Engagement up 100%

Fan Pass Live Facebook:

• People Reach up 10%
• Page Likes up 34%

Instagram:

• Account Reach up 18.4%

In January 2022, Friendable completed the acquisition of Artist Republik and FeaturedX. Together with the already successful Fan Pass Live artist platform, the company has positioned itself as the first 360 artist suite in the industry – offering independent musicians the ability to manage their own music from start to finish. Artists have several opportunities to earn revenue, from merchandise to ticket sales and monthly subscription fees for fans to exclusive artist-only contests. Each month Friendable promotes an artist contest for those signed up on their platform. The contest is a way for artists to earn additional funds and increase their exposure. For April, the Fan Pass Live Instagram account, @fanpasslive, posted the newest contest – Stream to Win. The top five artists with the most ticket sales in April will win free unlimited music distribution for a year. It is easy to participate; join Fan Pass Live, set your ticket price, invite fans, and keep 100% of ticket sales! As a bonus, artists who promote three streams on Instagram and tag @fanpasslive can win a free Grow with Us Campaign ($10 value) to add listeners to Spotify and Soundcloud. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Graphene face masks designed by Kronos remove 99.9% of bacteria, virus particles
• KNOS believes these are the highest filtration-efficiency numbers for any face masks in the market
• Kronos is focused on next-generation wellness consumer-electronics products and PPE solutions

Kronos Advanced Technologies (OTC: KNOS) is continuing its role as a leader in the world of advanced air filtration. The company offers N95 face masks made in the USA by a NIOSH-certified facility and Kronos-designed graphene face masks, an ideal addition to the company’s line of products designed to fight viruses and kill germs. “An N95 mask is a type of respirator that meets U.S. quality standards,” states the Mayo Clinic (https://ibn.fm/wI7kM). “An N95 offers the highest level of protection. It offers more protection than a medical mask does because it filters out both large and small particles when the wearer inhales. Nonsurgical N95s can be used by the general public.” According to Kronos CEO Michael Rubinov, “Our goal is to provide the best available protective face masks on the market for those in higher-exposure risk environments, with the best technology available. Our Kronos graphene technology achieves this not only as of the highest protection properties but also by completely reducing the number of viable bacteria and virus particles that are able to pass through the mask materials to zero” (https://ibn.fm/A1xB2). According to Kronos, its five-ply graphene face masks remove 99.9% of bacteria and virus particles compared to the common and far less efficacious ASTM level 3 mask. The company noted that ASTM level 3 is the FDA’s highest rating for medical and surgical face masks, and the Kronos face mask is the only five-ply graphene mask known to be manufactured in the United States. “With BFE and VFE levels over 99.9%, the company believes that these are the highest filtration efficiency numbers for any face masks in the market,” stated Kronos. “All test method acceptance criteria were met. Testing was performed in compliance with U.S. FDA good manufacturing practice (‘GMP’) regulations 21 CFR Parts 210, 211, and 820.” The need for high-quality masks continues, even as the COVID-19 pandemic appears to be easing in the United States. Some parts of the world are seeing spikes in numbers, and experts predict that the threat of COVID-19 is far from over. “Many health experts say the loosening of COVID restrictions is probably due to rising COVID fatigue, in which people are tired of mandates, lockdowns, and anxiety-inducing daily case and death numbers,” a recent “Fortune” article states. The article quoted Tedros Adhanom Ghebreyesus, director general of the World Health Organization (“WHO”): “In some countries, high vaccine coverage, combined with the lower severity of omicron, is driving a false narrative that the pandemic is over. . . . At the same time, low vaccine coverage and low testing rates in other countries are creating the ideal conditions for new variants to emerge.” The “Fortune” article noted the consensus among experts that new COVID variants will soon emerge that may or may not be more virulent; the delta and omicron variants are examples of variants that have already been identified. “The WHO has warned the next COVID variant will be more infectious than omicron, and it may be more deadly,” the article states. Kronos is focused on next-generation wellness consumer-electronics products and PPE solutions. Originally founded in 2002 and funded by the U.S. military to develop electrostatic air movers, the company has since evolved into the consumer air-purification space, initially focusing on developing, marketing and selling its proprietary air movement and purification technology. Its proprietary technology is now also being implemented in multiple standalone products for businesses, homes and vehicles of all types to move, sterilize and filter air. The company is exploring broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices, including schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and automobiles and commercial aircraft cabins. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

• Eat Well Investment Group Inc. is an investor and rapidly growing producer of nutritious plant-based foods
• Eat Well recently announced that its Belle Pulses subsidiary is increasing its legumes-based protein output capacity in response to global concerns about the food supply chain in the wake of the COVID pandemic and Russia’s war on Ukraine
• Russia and Ukraine are some of the world’s largest exporters of peas, as well as other consumer products whose commerce is threatened by the war’s devastation as well as the international community’s economic sanctions on Russia
• Another Eat Well subsidiary, Amara Organic Foods, recently announced it is increasing its baby food brand distribution through agreements with Sobeys and IGA national retail stores

The rising price of gasoline has drawn a great deal of attention from consumers as world events prompt inflation in key lifestyle sectors (https://ibn.fm/Inlqk), but disruptions to the global food supply chain as a result of these events have the potential to inflict a much greater harm on consumers’ lifestyles. Companies like Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) are taking an aggressive approach toward dealing with food supply chain concerns that have arisen in the wake of the COVID-19 pandemic’s years-long battering on global economies, followed by the devastation of a region known as the world’s breadbasket during Russia’s ongoing war against Ukraine (https://ibn.fm/2AF6a). The economic sanctions imposed on Russia’s international commerce as a result of the war has further hampered the global supply of products used in agricultural labor, as well as the fruits of agriculture that so many people are used to enjoying (https://ibn.fm/OUmxk). Eat Well Investment Group is stepping up its production of pulse-sourced protein (proteins from plants in a variety of legume families) to help meet the sudden demand for foods that can no longer be obtained from Russia and Ukraine. The company reported April 1 that it produced 90,000 metric tons (tonnes) of proteins from legumes such as peas, chickpeas, lentils and beans during 2021, and is taking steps to increase annual protein production capacity to nearly 100,000 metric tons at its subsidiary Belle Pulses’ flagship plant in Saskatchewan while also increasing annual production at a plant in the United States to 15,000 tonnes. It’s a fraction of the 1 million tonnes of peas Russia exports annually as well as the approximately 500,000 tonnes of peas exported by Ukraine each year. “It has always been our investment thesis that the globe will shift to more sustainable and environmentally friendly proteins. The next 24 months will be crucial for international food security as one of the world’s largest producers of fertilizer, agricultural crops and pulses is effectively closed off from the rest of the world,” Eat Well Group CEO and Director Marc Aneed stated (https://ibn.fm/e9XLX). “Belle is receiving increased recognition from international customers looking to secure quality, safe and reliable proteins at scale,” Eat Well Group Chief Investment Officer Mark Coles added. “Belle has emerged as a pivotal player in global pulse protein production and continues to draw significant interest in its products.” Belle Pulses is 100 percent owned by Eat Well Group and supplies customers in over 35 countries with its products. Another of Eat Well’s subsidiaries, Amara Organic Foods, has also increased the availability of its fast-growing baby food brands — adding distribution through select stores under the Sobeys and IGA national retail chains across Canada. “Sobeys and IGA stores (are) some of North America’s most well-known and established grocery retailers,” Aneed stated in the company’s news release (https://ibn.fm/4dyeX). “The demand for plant-based infant nutrition continues to be strong as we accelerate growth across Eat Well Group’s CPG sector. We congratulate the Amara team for ongoing success.” For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

In addition to high-profile speakers such as Facebook’s former head of advertising, the editor-in-chief of Forbes and many others, Noble Capital Markets just announced two more notable individuals that will be part of NobleCon18’s agenda next month at The Guitar Hotel near Miami. Brig. Gen. Holt, the Deputy United States Military Representative to the North Atlantic Treaty Organization (“NATO”), supports the Military Representative and the Chairman of the Joint Chiefs of Staff in executing the U.S. political-military mission at the North Atlantic Council. The general is a command pilot with more than 3,900 flying hours in a variety of aircraft. His dissertation was awarded a “with distinction” honor at the Royal Superior College of Defense in Brussels. Additionally, he has published a variety of papers across a range of national security issues and is a life member of the Wings Club and the Council on Foreign Relations. The general is uniquely qualified to opine on the Russian invasion of Ukraine. Chris Ruddy, CEO of Newsmax, founded Newsmax in 1998 to publish online and offline content in the fields of news, politics, health and finance. Newsmax.com ranks consistently as one of the country’s most trafficked news websites. Newsmax TV, a cable and over-the-top media service news channel started in 2014, is carried in more than 70 million U.S. homes. Additionally, Ruddy sits on the Board of Directors of the Financial Publishers Association, the industry organization representing investment publications that reach 25 million Americans monthly. A Newsweek cover story named him as one of America’s top 20 most influential news media personalities. Admission to NobleCon is free for all levels of investors from self-directed novices to institutional investors, thanks to Noble, Channelchek, Sponsors and The Presenting Companies. Attendance is limited to 1,000. To secure a ticket for the April 20-21 investor conference, visit https://nobleconference.com/register/investor-guest Full list of speakers: https://channelchek.com/news-channel/Scheduled_Speakers_NobleCon18 The presenting companies: https://channelchek.com/news-channel/NobleCon18_Presenting_Companies